Announcement PDF RNS Number : 0253H Shield Therapeutics PLC 20 March 2020 TR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: Shield Therapeutics Plc 1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate) Non-UK issuer 2. Reason for the notification (please mark the appropriate box or boxes with an "X") An acquisition or disposal of voting rights X An acquisition or disposal of financial instruments An event changing the breakdown of voting rights Other (please specify)iii: 3. Details of person subject to the notification obligationiv Name Richard Griffiths and controlled undertakings City and country of registered office (if applicable) St Helier, Jersey 4. Full name of shareholder(s) (if different from 3)v Name City and country of registered office (if applicable) 5. Date on which the threshold was crossed or reached vi: 19 March 2020 6. Date on which issuer notified (DD/MM/YYYY): 20 March 2020 7. Total positions of person(s) subject to the notification obligation Resulting situation % of voting rights attached to shares (total of 8. A) % of voting rights through financial instruments (total of 8.B 1 + 8.B 2) Total of both in % (8.A + 8.B) < 3.00% 0.00% < 3.00% Total number of voting rights of issuervii on the date on which threshold was crossed or reached Position of previous notification (if applicable) 117,188,657 3.96% 0.00% 3.96% 8. Notified details of the resulting situation on the date on which the threshold was crossed or reached viii A: Voting rights attached to shares Class/type of shares ISIN code (if possible) Number of voting rightsix % of voting rights Indirect Direct Direct Indirect (Art 9 of Directive 2004/109/EC) (DTR5.1) (Art 10 of Directive 2004/109/EC) (DTR5.2.1) (Art 9 of Directive 2004/109/EC) (DTR5.1) (Art 10 of Directive 2004/109/EC) (DTR5.2.1) < 3.00% 0.00% < 3.00% 0.00% Ordinary £0.015 GB00BYV81293 < 3.00% SUBTOTAL 8. A < 3.00% B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a)) Type of financial instrument Expiration datex Exercise/ Conversion Periodxi Number of voting rights that may be acquired if the instrument is exercised/converted. % of voting rights SUBTOTAL 8. B 1 B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b)) Type of financial instrument Expiration date x Exercise/ Conversion Period xi Physical or cash settlementxii SUBTOTAL 8.B.2 Number of voting rights % of voting rights 9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an "X") Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary) % of voting rights if it equals or is higher than the notifiable threshold Namexv % of voting rights through financial instruments if it equals or is higher than the notifiable threshold 10. In case of proxy voting, please identify: Name of the proxy holder NA The number and % of voting rights held NA The date until which the voting rights will be held NA 11. Additional informationxvi Place of completion Date of completion St Helier, Jersey 20 March 2020 Total of both if it equals or is higher than the notifiable threshold This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com. END HOLJMMBTMTJTBAM